KN 032Alternative Names: KN-032
Latest Information Update: 14 Jul 2016
At a glance
- Originator Alphamab
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 May 2015 Preclinical trials in Cancer in China (unspecified route)